AR082077A1 - Compuestos para el tratamiento de trastornos y enfermedades del segmento posterior - Google Patents

Compuestos para el tratamiento de trastornos y enfermedades del segmento posterior

Info

Publication number
AR082077A1
AR082077A1 ARP110102374A ARP110102374A AR082077A1 AR 082077 A1 AR082077 A1 AR 082077A1 AR P110102374 A ARP110102374 A AR P110102374A AR P110102374 A ARP110102374 A AR P110102374A AR 082077 A1 AR082077 A1 AR 082077A1
Authority
AR
Argentina
Prior art keywords
phenyl
urea
amino
pyridin
tolyl
Prior art date
Application number
ARP110102374A
Other languages
English (en)
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of AR082077A1 publication Critical patent/AR082077A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Uso de ciertos compuestos de urea, para el tratamiento de trastornos de la retina asociados con la angiogénesis y/o neovascularización ocular patológica.Reivindicación 1: El uso de una composición oftálmica que comprende una cantidad terapéuticamente eficaz de por lo menos un compuesto seleccionado del grupo formado por 1-[4-(3-amino-1H-pirazolo[3,4-c]piridin-4-il)-fenil]-3-m-tolil-urea, 1-[4-(4-amino-tieno[2,3-d]pirimidin-5-il)-fenil]-3-m-tolil-urea, 1-[4-(3-amino-1H-indazol-4-il)-fenil]-3-(3-hidroxi-5-metil-fenil)-urea, 1-{4-[3-amino-7-(2-metoxi-etoxi)-1H-indazol-4-il]-fenil}-3-m-tolil-urea, 1-[4-(4-amino-tieno[3,2-c]piridin-3-il)-fenil]-3-m-tolil-urea, 1-[4-(4-amino-7-piridin-4-il-tieno[3,2-c]piridin-3-il)-fenil]-3-m-tolil-urea, 1-[4-(4-amino-7-piridin-3-il-tieno[3,2-c]piridin-3-il)-fenil]-3-m-tolil-urea, y sus sales farmacéuticamente aceptables, para preparar un medicamento para tratar la neovascularización del segmento posterior, AMD, DR, y/o edema de retina.
ARP110102374A 2010-07-02 2011-07-01 Compuestos para el tratamiento de trastornos y enfermedades del segmento posterior AR082077A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36100310P 2010-07-02 2010-07-02

Publications (1)

Publication Number Publication Date
AR082077A1 true AR082077A1 (es) 2012-11-07

Family

ID=44543755

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110102374A AR082077A1 (es) 2010-07-02 2011-07-01 Compuestos para el tratamiento de trastornos y enfermedades del segmento posterior

Country Status (13)

Country Link
US (1) US20120004245A1 (es)
EP (1) EP2588098A1 (es)
JP (1) JP2013530230A (es)
KR (1) KR20130102524A (es)
CN (1) CN102985084A (es)
AR (1) AR082077A1 (es)
AU (1) AU2011271518A1 (es)
BR (1) BR112012033388A2 (es)
CA (1) CA2799587A1 (es)
MX (1) MX2012014487A (es)
TW (1) TW201206929A (es)
UY (1) UY33481A (es)
WO (1) WO2012003141A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
US8197435B2 (en) 2006-05-02 2012-06-12 Emory University Methods and devices for drug delivery to ocular tissue using microneedle
EP3520749A1 (en) 2010-10-15 2019-08-07 Clearside Biomedical, Inc. Device for ocular access
US9487483B2 (en) * 2012-06-28 2016-11-08 Novartis Ag Complement pathway modulators and uses thereof
JP6273274B2 (ja) * 2012-06-28 2018-01-31 ノバルティス アーゲー 補体経路モジュレーターおよびその使用
WO2014002059A1 (en) * 2012-06-29 2014-01-03 Novartis Ag CRYSTALLINE FORMS OF 1-(2-((1R,3S,5R)-3-(((R)-1-(3-chloro-2-fluorophenyl)ethyl)carbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1Hpyrazolo[3,4-c]pyridine-3-carboxamide
EP2872503B1 (en) * 2012-07-12 2018-06-20 Novartis AG Complement pathway modulators and uses thereof
MX2015005839A (es) 2012-11-08 2015-12-17 Clearside Biomedical Inc Metodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos.
ES2831625T3 (es) 2013-02-20 2021-06-09 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos
CN105246529B (zh) 2013-05-03 2019-06-14 科尼尔赛德生物医学公司 用于眼部注射的设备和方法
WO2014197317A1 (en) 2013-06-03 2014-12-11 Clearside Biomedical, Inc. Apparatus and methods for drug delivery using multiple reservoirs
WO2014201127A2 (en) 2013-06-11 2014-12-18 Kala Pharmaceuticals, Inc. Urea derivatives and uses thereof
JP2017524419A (ja) 2014-06-20 2017-08-31 クリアサイド バイオメディカル，インコーポレイテッド 薬剤送達のための挿入深さを制御するための可変径カニューレ及び方法
USD750223S1 (en) 2014-10-14 2016-02-23 Clearside Biomedical, Inc. Medical injector for ocular injection
CA2969467A1 (en) 2014-12-10 2016-06-16 Kala Pharmaceuticals, Inc. 1-amino-triazolo(1,5-a)pyridine-substituted urea derivative and uses thereof
WO2017139375A1 (en) 2016-02-10 2017-08-17 Clearside Biomedical, Inc. Ocular injection kit, packaging, and methods of use
WO2017192565A1 (en) 2016-05-02 2017-11-09 Clearside Biomedical, Inc. Systems and methods for ocular drug delivery
CN110177527B (zh) 2016-08-12 2022-02-01 科尼尔赛德生物医学公司 用于调节药剂递送用针的插入深度的装置和方法
WO2018204515A1 (en) 2017-05-02 2018-11-08 Georgia Tech Research Corporation Targeted drug delivery methods using a microneedle

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030181468A1 (en) * 2002-03-21 2003-09-25 Michaelides Michael R. Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
US7297709B2 (en) * 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US20050020619A1 (en) 2003-07-24 2005-01-27 Patrick Betschmann Thienopyridine kinase inhibitors
US20050026944A1 (en) 2003-07-24 2005-02-03 Patrick Betschmann Thienopyridine and furopyridine kinase inhibitors
JP5112875B2 (ja) 2004-10-29 2013-01-09 アボット・ラボラトリーズ 新規なキナーゼ阻害薬
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
US20070060887A1 (en) 2005-08-22 2007-03-15 Marsh David A Ophthalmic injector

Also Published As

Publication number Publication date
WO2012003141A1 (en) 2012-01-05
TW201206929A (en) 2012-02-16
US20120004245A1 (en) 2012-01-05
BR112012033388A2 (pt) 2016-11-22
JP2013530230A (ja) 2013-07-25
CA2799587A1 (en) 2012-01-05
MX2012014487A (es) 2013-02-21
CN102985084A (zh) 2013-03-20
UY33481A (es) 2011-10-31
KR20130102524A (ko) 2013-09-17
EP2588098A1 (en) 2013-05-08
AU2011271518A1 (en) 2012-12-13

Similar Documents

Publication Publication Date Title
AR082077A1 (es) Compuestos para el tratamiento de trastornos y enfermedades del segmento posterior
DOP2019000187A (es) Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
MX2016014634A (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
BR112017007662A2 (pt) composto, composição farmacêutica, processo de elaboração de uma composição farmacêutica, método de tratamento de distúrbio ou doença relativa a er, kit de tratamento e uso de composto
CA2925624C (en) Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
BR112017016131A2 (pt) ?uso de fenilpiridinas, fenilpirimidinas, processos para preparação de fenilpirimidinas e para preparação de composições ativas herbicidas, pirimidinas, composição herbicida, e, método para controlar vegetação indesejada?.
PH12016501651B1 (en) Triazine compound and use thereof for medical purposes
JP2016515522A5 (es)
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
CO6630133A2 (es) Compuestos de pirazol -4-il heterociclil -carboxamida y métodos de uso
AR090712A1 (es) Agentes para tratar trastornos que implican la modulacion de receptores de rianodina
MX2019002439A (es) Derivados de n-(piridin-2-il) piridina-sulfonamida y su uso en el tratamiento de enfermedades.
BR112014001880A2 (pt) derivados de carboxamida e ureia contendo pirazol heteroaromáticos substituídos como ligantes de receptor vaniloide
RU2017114352A (ru) АНТАГОНИСТЫ ИНТЕГРИНА ανβ6
MX2021007592A (es) Compuestos macrociclicos y su uso en el tratamiento de enfermedades.
BR112014027117A8 (pt) Derivados de pirazol aminopirimidina como moduladores de lrrk2, seus usos, e composição
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
BR112014001908A2 (pt) derivados aza heterocíclicos substituídos
MY201535A (en) Therapeutic compounds
CO2018010951A2 (es) Compuestos de cinnolin-4-amina y su uso en el tratamiento del cáncer
CL2008003362A1 (es) Compuestos heterociclos derivados de tieno(2,3-d)pirimidinona, con actividad estimuladora del receptor ampa; composicion farmaceutica; y uso de los compuestos en el tratamiento de afecciones siquiatricas tales como esquizofrenia, depresion y trastornos del aprendizaje.
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
EA201390618A1 (ru) Режимы дозирования при лечении офтальмологического сосудистого заболевания
PH12018500469A1 (en) Sulfonamide compounds as voltage-gated sodium channel modulators

Legal Events

Date Code Title Description
FB Suspension of granting procedure